Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Provectus Biopharmaceuticals Inc PVCT

Healthcare

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform... see more

Add To Watchlist

Recent & Breaking News (OTCQB:PVCT)

Provectus Biopharmaceuticals' PV-10 Data to Feature in Poster Presentation by Moffitt Cancer Center at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 2, 2014

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire April 1, 2014

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference

Business Wire April 1, 2014

Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanoma

Business Wire March 24, 2014

Provectus Appoints Dr. Joseph M. Chalil to Strategic Advisory Board

Business Wire March 19, 2014

PV-10 Immune Mechanism Data to Be Presented at the American Association for Cancer Research Annual Meeting

Business Wire March 6, 2014

Sanofi's CEO Admits Lackluster Drug Development Decade but Defends Its Pipeline: Sanofi (OTCQB: SNYNF), Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Provectus Pharmaceuticals (OTC: PVCT)

Accesswire February 10, 2014

TrendingWallStreet.com Begins Trending PVCT, ORMP, KO, and MCIG

Accesswire February 4, 2014

TrendingWallStreet.com Releases Trend Coverage on TWTR, DRNA, PVCT, and GERN

Accesswire January 31, 2014

Tranzbyte's Medical-Marijuana Dispensary Deal Falls Apart: Tranzbyte Corp. (OTCPINK: ERBB), Neutra Corp. (OTCQB: NTRR), Provectus Pharmaceuticals (OTC: PVCT)

Accesswire January 30, 2014

Provectus Announces PV-10's Assessment for Drug-Drug Interaction Potential is Subject of Article Published by Xenobiotica

Business Wire January 28, 2014

Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)

Accesswire January 27, 2014

Provectus's PV-10 Path to Initial Approval in U.S. Now Clear Per FDA Meeting Minutes

Business Wire January 24, 2014

Provectus' Wild Volume Ride Ends With 64.18% Loss for the Day: Provectus Pharmaceutical Inc. (OTCQB: PVCT), Royal Dutch Shell Plc (OTCQB: RYDAF), Fannie Mae (OTCQB: FNMA)

Accesswire January 24, 2014

TrendingWallStreet.com Releases Trend Reports on KWK, DRYS, PVCT, and ICLD

Accesswire January 3, 2014

TrendingWallStreet.com Initiates Analysis on TWTR, TSLA, PVCT, and DDD

Accesswire December 27, 2013

TrendingWallStreet.com Announces Analysis on FB, KORS, NNRX, and PVCT

Accesswire December 24, 2013

TrendingWallStreet.com Provides Analysis on PVCT, F, EONC, and APPZ

Accesswire December 19, 2013

Provectus Type C Meeting With FDA Oncology Division Held December 16, 2013

Business Wire December 18, 2013

TrendingWallStreet.com Begins Research on FISV, NNRX, WMB, and PVCT

Accesswire December 18, 2013